Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + lenalidomide
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Zanubrutinib + lenalidomide is an investigational combination therapy consisting of two small molecule drugs, zanubrutinib and lenalidomide. Zanubrutinib is a next-generation, highly selective Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, leading to inhibition of malignant B-cell proliferation and survival. Lenalidomide is an immunomodulatory agent with direct anti-tumor activity and indirect effects through enhancement of immune responses. The combination has been studied primarily in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies, showing promising efficacy and manageable safety profiles in early-phase clinical trials[4][7]. The regimen may be particularly relevant for patients who are unfit for standard chemotherapy or stem cell transplantation.
- Other names
- ZR²ZR2ZR-2ZR 2
02
Targets
CRBN (Cereblon)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + lenalidomide.